title: [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act &#34;A rebirth of hope&#34;].
abstract: Despite the clinical use of statins to reduce serum levels of LDL cholesterol and treat atherosclerotic cardiovascular disease, a high proportion of patients remain at significant residual cardiovascular risk. In this context, low HDL cholesterol levels are an additional risk factor and intervention studies suggest that a fraction of the cardiovascular protection achieved with pharmacotherapy is explained specifically by the increase in serum levels of HDL cholesterol. Pharmacological inhibitors of the cholesteryl ester transfer protein (CETP) can induce a significant elevation in HDL cholesterol and, potentially, lead to better control of residual cardiovascular risk beyond the benefit demonstrated by statins. While the use of torcetrapib had unexpected side effects, dalcetrapib and anacetrapib are new CETP inhibitors with a better safety profile and are currently under study to evaluate their effects on vascular lesions and clinical events in patients at high cardiovascular risk. If these studies show positive findings, we will witness a new biomedical advance as significant as was the clinical.
authors: Departamento de Diabetes, Nutrición y Metabolismo, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors: Antonio
authors: A
authors: Arteaga
authors: Attilio
authors: A
authors: Rigotti
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D006801:Humans
chemical_list: D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins